A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

NCT02688933 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

638

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 1 Diabetes Mellitus

Interventions

DRUG: HOE901-U300 (Insulin Glargine 300 U/ml)
DRUG: Lantus (Insulin Glargine 100 U/ml)
DRUG: Mandated back ground therapy

Sponsor

Sanofi